TY  - GEN
AU  - Kühnl,A
AU  - Cunningham,D
AU  - Counsell,N
AU  - Hawkes,E A
AU  - Qian,W
AU  - Smith,P
AU  - Chadwick,N
AU  - Lawrie,A
AU  - Mouncey,P
AU  - Jack,A
AU  - Pocock,C
AU  - Ardeshna,K M
AU  - Radford,J
AU  - McMillan,A
AU  - Davies,J
AU  - Turner,D
AU  - Kruger,A
AU  - Johnson,P W
AU  - Gambell,J
AU  - Rosenwald,A
AU  - Ott,G
AU  - Horn,H
AU  - Ziepert,M
AU  - Pfreundschuh,M
AU  - Linch,D
TI  - Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
SN  - 1569-8041
PY  - 2018///0129
KW  - Age Factors
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - genetics
KW  - Cyclophosphamide
KW  - Doxorubicin
KW  - Drug Administration Schedule
KW  - Female
KW  - Gene Rearrangement
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Patient Selection
KW  - Precision Medicine
KW  - Prednisone
KW  - Proto-Oncogene Proteins c-bcl-2
KW  - Proto-Oncogene Proteins c-bcl-6
KW  - Proto-Oncogene Proteins c-myc
KW  - Risk Factors
KW  - Rituximab
KW  - Time Factors
KW  - Treatment Outcome
KW  - United Kingdom
KW  - Vincristine
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
UR  - https://doi.org/10.1093/annonc/mdx128
ER  -